{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:44:10Z","timestamp":1791211450079,"version":"4.1.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"\n Importance<\/jats:title>\n Gabapentin prescriptions have drastically increased in the US due to off-label prescribing in settings such as opioid use disorder (OUD) treatment to manage a range of comorbid conditions and withdrawal symptoms, despite a lack of evidence.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the purpose and associated risks of off-label gabapentin use in OUD treatment.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective recurrent-event case-control study with a crossover design used administrative claims data from MarketScan Commercial and Multi-State Medicaid databases from January 1, 2006, to December 31, 2016. Individuals aged 12 to 64 years with an OUD diagnosis and filling buprenorphine prescriptions were included in the primary analysis conducted from July 1, 2022, through June 1, 2023. Unit of observation was the person-day.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Days covered by filled gabapentin prescriptions.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n Primary outcomes were receipt of gabapentin in the 90 days after initiation of buprenorphine treatment and drug-related poisoning. Drug-related poisonings were defined using codes from\n International Classification of Diseases, Ninth Revision<\/jats:italic>\n , and\n International Statistical Classification of Diseases and Related Health Problems, Tenth Revision<\/jats:italic>\n .\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 109 407 patients were included in the analysis (mean [SD] age, 34.0 [11.2] years; 60 112 [54.9%] male). Among the 29 967 patients with Medicaid coverage, 299 (1.0%) were Hispanic, 1330 (4.4%) were non-Hispanic Black, 23 112 (77.1%) were non-Hispanic White, and 3399 (11.3%) were other. Gabapentin was significantly less likely to be prescribed to Black or Hispanic patients, and more likely to be prescribed to female patients, those with co-occurring substance use or mood disorders, and those with comorbid physical conditions such as neuropathic pain. Nearly one-third of persons who received gabapentin (4336 [31.1%]) had at least 1 drug-related poisoning after initiating buprenorphine treatment, compared with 13\u202f856 (14.5%) among persons who did not receive gabapentin. Adjusted analyses showed that days of gabapentin use were not associated with hospitalization for drug-related poisoning (odds ratio, 0.98 [95% CI, 0.85-1.13]). Drug-related poisoning risks did not vary based on dosage.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Gabapentin is prescribed in the context of a myriad of comorbid conditions. Even though persons receiving gabapentin are more likely to have admissions for drug-related poisoning, these data suggest that gabapentin is not associated with an increased risk of drug-related poisoning alongside buprenorphine in adjusted analyses. More data on the safety profile of gabapentin in OUD settings are needed.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2023.3145","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T11:03:35Z","timestamp":1693998215000},"page":"1269","source":"Crossref","is-referenced-by-count":17,"title":["Gabapentin Use Among Individuals Initiating Buprenorphine Treatment for Opioid Use Disorder"],"prefix":"10.1001","volume":"80","author":[{"given":"Matthew S.","family":"Ellis","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Washington University in St Louis, School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Y.","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Washington University in St Louis, School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitor S.","family":"Tardelli","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"},{"name":"Translational Addictions Research Laboratory, Centre for Addictions and Mental Health, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiago M.","family":"Fidalgo","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mance E.","family":"Buttram","sequence":"additional","affiliation":[{"name":"Department of Health, Human Performance and Recreation, University of Arkansas, Fayetteville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Grucza","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, St Louis University, St Louis, Missouri"},{"name":"Department of Health and Outcomes Research, St Louis University, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"yoi230067r1","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1001\/jamainternmed.2017.7856","article-title":"Gabapentinoid use in the United States 2002 through 2015.","volume":"178","author":"Johansen","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"2","key":"yoi230067r2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1001\/jamainternmed.2022.5268","article-title":"Trends in the concurrent prescription of opioids and gabapentin in the US, 2006 to 2018.","volume":"183","author":"Peet","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"6","key":"yoi230067r3","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1111\/jgs.v71.6","article-title":"Psychotropic substitutions: out of the frying pan and into the fire.","volume":"71","author":"Reppas-Rindlisbacher","year":"2023","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"yoi230067r4","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1001\/jamainternmed.2019.0086","article-title":"A clinical overview of off-label use of gabapentinoid drugs.","volume":"179","author":"Goodman","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"3","key":"yoi230067r5","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/s41380-021-01386-6","article-title":"Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: systematic review, meta-analysis, and rationale.","volume":"27","author":"Hong","year":"2022","journal-title":"Mol Psychiatry"},{"issue":"2","key":"yoi230067r6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jpain.2015.12.008","article-title":"Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists\u2019 Committee on Regional Anesthesia, Executive Committee, and Administrative Council.","volume":"17","author":"Chou","year":"2016","journal-title":"J Pain"},{"issue":"1","key":"yoi230067r7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1176\/appi.ajp.2017.1750101","article-title":"The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder.","volume":"175","author":"Reus","year":"2018","journal-title":"Am J Psychiatry"},{"key":"yoi230067r8","doi-asserted-by":"publisher","DOI":"10.1177\/1178221818801311","article-title":"Gabapentin for off-label use: evidence-based or cause for concern?","volume":"12","author":"Peckham","year":"2018","journal-title":"Subst Abuse"},{"issue":"1","key":"yoi230067r9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1037\/adb0000337","article-title":"A qualitative analysis of gabapentin misuse and diversion among people who use drugs in Appalachian Kentucky.","volume":"32","author":"Vickers Smith","year":"2018","journal-title":"Psychol Addict Behav"},{"key":"yoi230067r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109713","article-title":"Understanding motivations and use typologies of gabapentin with opioid agonist medications.","volume":"242","author":"Ellis","year":"2023","journal-title":"Drug Alcohol Depend"},{"key":"yoi230067r11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3389\/fpsyt.2019.00228","article-title":"Use of gabapentin in the treatment of substance use and psychiatric disorders: a systematic review.","volume":"10","author":"Ahmed","year":"2019","journal-title":"Front Psychiatry"},{"issue":"2","key":"yoi230067r12","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1080\/10550490601186238","article-title":"Gabapentin in comorbid anxiety and substance use.","volume":"16","author":"Verduin","year":"2007","journal-title":"Am J Addict"},{"issue":"7","key":"yoi230067r13","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/add.v111.7","article-title":"Gabapentin misuse, abuse and diversion: a systematic review.","volume":"111","author":"Smith","year":"2016","journal-title":"Addiction"},{"issue":"1","key":"yoi230067r14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40265-020-01432-7","article-title":"Abuse and misuse of pregabalin and gabapentin: a systematic review update.","volume":"81","author":"Evoy","year":"2021","journal-title":"Drugs"},{"issue":"9","key":"yoi230067r15","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/pds.v26.9","article-title":"Law enforcement-derived data on gabapentin diversion and misuse, 2002-2015: diversion rates and qualitative research findings.","volume":"26","author":"Buttram","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"yoi230067r16","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1093\/ajhp\/zxab486","article-title":"State-level response to gabapentin misuse in the United States: implications and future direction.","volume":"79","author":"Karavolis","year":"2022","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"yoi230067r17","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1080\/20961790.2021.1991075","article-title":"Gabapentin prevalence: clinical and forensic experience in St. Louis, Missouri, USA.","volume":"6","author":"Riley","year":"2021","journal-title":"Forensic Sci Res"},{"issue":"19","key":"yoi230067r18","doi-asserted-by":"publisher","first-page":"664","DOI":"10.15585\/mmwr.mm7119a3","article-title":"Notes from the field: trends in gabapentin detection and involvement in drug overdose deaths\u201423 states and the District of Columbia, 2019-2020.","volume":"71","author":"Mattson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"yoi230067r19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.31647","article-title":"Association of gabapentinoids with the risk of opioid-related adverse events in surgical patients in the United States.","volume":"3","author":"Bykov","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"10","key":"yoi230067r20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002396","article-title":"Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study.","volume":"14","author":"Gomes","year":"2017","journal-title":"PLoS Med"},{"issue":"1","key":"yoi230067r21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1213\/ANE.0000000000001719","article-title":"Multimodal analgesic therapy with gabapentin and its association with postoperative respiratory depression.","volume":"125","author":"Cavalcante","year":"2017","journal-title":"Anesth Analg"},{"key":"yoi230067r22","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.2147\/JPR","article-title":"Risk of respiratory depression with opioids and concomitant gabapentinoids.","volume":"10","author":"Savelloni","year":"2017","journal-title":"J Pain Res"},{"issue":"3","key":"yoi230067r23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000355268","article-title":"Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers.","volume":"20","author":"Baird","year":"2014","journal-title":"Eur Addict Res"},{"issue":"6","key":"yoi230067r24","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1176\/appi.ajp.2014.13111526","article-title":"Potentiation of the effect of buprenorphine\/naloxone with gabapentin or quetiapine.","volume":"171","author":"Reeves","year":"2014","journal-title":"Am J Psychiatry"},{"key":"yoi230067r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109400","article-title":"Nonmedical use of gabapentin and opioid agonist medications in treatment-seeking individuals with opioid use disorder.","volume":"234","author":"Ellis","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"yoi230067r26","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1176\/appi.ajp.2020.20081174","article-title":"Association between benzodiazepine or z-drug prescriptions and drug-related poisonings among patients receiving buprenorphine maintenance: a case-crossover analysis.","volume":"178","author":"Xu","year":"2021","journal-title":"Am J Psychiatry"},{"key":"yoi230067r27","doi-asserted-by":"publisher","DOI":"10.1007\/s11469-022-00985-w","article-title":"Impact of alternative ways to operationalize buprenorphine treatment duration on understanding continuity of care for opioid use disorder.","author":"Dong","year":"2022","journal-title":"Int J Ment Health Addict"},{"issue":"2","key":"yoi230067r28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1176\/appi.ajp.2019.19060612","article-title":"Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder.","volume":"177","author":"Williams","year":"2020","journal-title":"Am J Psychiatry"},{"key":"yoi230067r29","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1093\/ajhp\/zxac140","article-title":"Gabapentin initiation in the inpatient setting: a characterization of prescribing.","volume":"79","author":"Waterloo","year":"2022","journal-title":"Am J Health Syst Pharm"},{"key":"yoi230067r31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1467-9531.2006.00177.x","article-title":"Fixed-effects methods for the analysis of nonrepeated events.","volume":"36","author":"Allison","year":"2006","journal-title":"Sociol Methodol"},{"issue":"5","key":"yoi230067r32","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1093\/ije\/dyu081","article-title":"Exchangeability in the case-crossover design.","volume":"43","author":"Mittleman","year":"2014","journal-title":"Int J Epidemiol"},{"issue":"10","key":"yoi230067r33","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/aje\/kww079","article-title":"Persistent user bias in case-crossover studies in pharmacoepidemiology.","volume":"184","author":"Hallas","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"5","key":"yoi230067r34","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1111\/add.v115.5","article-title":"Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine.","volume":"115","author":"Park","year":"2020","journal-title":"Addiction"},{"issue":"5","key":"yoi230067r35","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.11634","article-title":"Analysis of stimulant prescriptions and drug-related poisoning risk among persons receiving buprenorphine treatment for opioid use disorder.","volume":"5","author":"Mintz","year":"2022","journal-title":"JAMA Netw Open"},{"key":"yoi230067r30","unstructured":"National Center for Injury Prevention and Control (US) Division of Unintentional Injury Prevention; Health Systems and Trauma Systems Branch; Prescription Drug Overdose Team. Prescription drug overdose data & statistics: guide to ICD-9-CM and ICD-10 codes related to poisoning and pain. August 12, 2013. Accessed July 29, 2022. https:\/\/stacks.cdc.gov\/view\/cdc\/59394"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2809162\/jamapsychiatry_ellis_2023_oi_230067_1700673912.91701.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T11:05:16Z","timestamp":1701860716000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2809162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.3145","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}